Beijing Xinyi ddPCR instrument renewal agency agreement work completed successfully!

On December 30, 2020, Wu Guanghui, general manager of Guangzhou laishang Biotechnology Co., Ltd., signed a contract with Beijing Xinyi Biotechnology Co., Ltd., and jointly completed the renewal of the 2021 agency agreement on behalf of Wan Jinhong, manager of South China. With the joint efforts of both sides, the market promotion work in the past year has been carried out smoothly and orderly, with rapid development momentum, and the market prospect has reached the ideal expectation. Through friendly exchanges, both sides agreed that in the next year's market promotion work, we should continue to work closely and actively to lay a good foundation for the comprehensive promotion of the market in Guangdong Province.

Targeting one, founded in 2015, is a bio high-tech company driven by core technologies and with global competitiveness. It has a high standard production base for biomedical instruments, consumables and in vitro diagnostic reagents in Zhongguancun Science Park. In the field of ddPCR, the company has the whole system R & D capabilities from chips, instruments, software to raw materials, reagents and consumables, and has applied for more than 90 patents at home and abroad. What Xinyi biology provides is not only a set of instrument system or a diagnosis project solution, but also a wide range of scientific research and diagnosis cooperation with users. We are willing to adhere to the development concept of "innovation, precision, heart for you", provide better services for users, and jointly promote the development of ddPCR technology to benefit the society.